Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Comment by Winnipeg40on Oct 15, 2022 12:42pm
224 Views
Post# 35026771

RE:New Article

RE:New ArticleThey do NOT have a priorty review voucher.  They may be eligible to receive one however.  My prediction is that before the trial is completed, MPH will be out of money, the drugstore purchase is a disaster and Zypitimag sales are not increasing in line with what they paid (at least supposed to have paid as I have not seen any payments through the cash flow statement lately)  and Aggrastat is soon off patent and  and Friesen will loan the company money at an egregious share value exchange amount so he can take any and all the gravy if the trial is successful and if not,  doesnt really matter as his staff of about 12 in 11,000 square feet in a building he owns that  has MPH paying rent has made him wealhty already and the companies he owns has already stripped millions out of MPH so it really doesnt matter to him.  Trial successful he wins, Trial unsuccessful he has already become rich
<< Previous
Bullboard Posts
Next >>